Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vera Therapeutics (VERA)
NASDAQ:VERA
Vera Therapeutics (VERA) Stock Price & Analysis
218 Followers
VERA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.73 - $50.78
Previous Close$36.95
Volume916.86K
Average Volume (3M)955.73K
Market Cap
$2.03B
Enterprise Value$1.92B
Total Cash (Recent Filing)$160.72M
Total Debt (Recent Filing)$53.71M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Aug 08, 2024EPS Estimate
-$0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.04
Shares Outstanding54,701,217
10 Day Avg. Volume713,755
30 Day Avg. Volume955,727
Standard Deviation0.37
R-Squared0.02
Alpha0.07
Financial Highlights & Ratios
Price to Book (P/B)5.74
Price to Sales (P/S)1048.35
Price to Cash Flow (P/CF)-15.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue996.98
Enterprise Value/Gross Profit996.98
Enterprise Value/Ebitda-26.91
Forecast
1Y Price Target
$55.57Price Target Upside46.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Vera Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsVera recently presented positive 72-week data from the Phase IIb ORIGIN study with atacicept in IgA nephropathy, showing consistent and sustained reductions in harmful proteins and stabilization of kidney function.
Market OpportunityThe acquisition of Alpine Immune Sciences by Vertex for approximately $4.9 billion validates the multi-billion dollar commercial opportunity in IgA nephropathy and potential benefits of inhibiting BLyS/APRIL.
Safety ProfileBoth doses of the treatment have been generally well-tolerated with no severe infections or significant adverse effects reported, pointing to a favorable safety profile.
Bears Say
Analyst CredibilityInvestors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report.
Financial PerformanceVERA reported a net loss of $96MM for the year-end, indicating financial challenges.
Potential Conflict Of InterestJ.P. Morgan expects to receive, or intends to seek, compensation for investment banking services in the next three months from Vera Therapeutics.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
VERA FAQ
What was Vera Therapeutics’s price range in the past 12 months?
Vera Therapeutics lowest stock price was $7.73 and its highest was $50.78 in the past 12 months.
What is Vera Therapeutics’s market cap?
Currently, no data Available
When is Vera Therapeutics’s upcoming earnings report date?
Vera Therapeutics’s upcoming earnings report date is Aug 08, 2024 which is in 68 days.
How were Vera Therapeutics’s earnings last quarter?
Vera Therapeutics released its earnings results on May 09, 2024. The company reported -$0.56 earnings per share for the quarter, missing the consensus estimate of -$0.53 by -$0.03.
Is Vera Therapeutics overvalued?
According to Wall Street analysts Vera Therapeutics’s price is currently Undervalued.
Does Vera Therapeutics pay dividends?
Vera Therapeutics does not currently pay dividends.
What is Vera Therapeutics’s EPS estimate?
Vera Therapeutics’s EPS estimate is -$0.56.
How many shares outstanding does Vera Therapeutics have?
Vera Therapeutics has 54,916,817 shares outstanding.
What happened to Vera Therapeutics’s price movement after its last earnings report?
Vera Therapeutics reported an EPS of -$0.56 in its last earnings report, missing expectations of -$0.53. Following the earnings report the stock price went down -5.808%.
Which hedge fund is a major shareholder of Vera Therapeutics?
Among the largest hedge funds holding Vera Therapeutics’s share is Woodline Partners LP. It holds Vera Therapeutics’s shares valued at 41M.
---
Vera Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$55.57 (46.28% Upside)
$55.57 (46.28% Upside)
Blogger Sentiment
Bullish
VERA Sentiment 71%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $40.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
361.29%
12-Months-Change
Fundamentals
Return on Equity
-36.89%
Trailing 12-Months
Asset Growth
100.07%
Trailing 12-Months
Company Description
Vera Therapeutics
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
---
VERA Stock 12 Month Forecast
Average Price Target
$55.57
▲(46.28% Upside)
Technical Analysis
Best Analysts Covering VERA
1 Year
1 Year Success Rate
8/11 ratings generated profit
1 Year Average Return
+163.16%
reiterated a buy rating 4 months ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +163.16% per trade.
---